Current clinical evidence supports the use of GLP-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events, including myocardial infarction, particularly in patients with type 2 diabetes and high cardiovascular risk. The gene discussed is GCG; the disease is myocardial infarction.